What are you looking for?
Our expertise in Pharma
Innovations in the Pharmacy sector, for example, innovations relating to drug repurposing and (re) development of medications ensure a continuous stream of innovations within this sector. NLO's Pharma teams consist of attorneys with diverse, relevant specialisations. Our IP specialists have acquired experience in either business or research institutes before working at NLO. They are familiar with the ins & outs in Pharmacy, including current developments and regulations.
Our clients
NLO serves clients in the Pharma sector in which our experts can stand by your side to advise your company and innovations about the importance of patents and intellectual property.
WHAT OUR CLIENTS SAY ABOUT WORKING WITH NLO
Article FD
What if an existing medicine for diabetes can also be used for the untreatable disease Alzheimer?
Researchers regularly develop new purposes for existing drugs. This so called ‘drug repurposing’ may allow patients to access a therapy for the first time or improve current treatment. In addition, the development process can be faster than for a newly developed drug. Therefore, costs are often lower and patients may get access to therapy sooner. A new application for an existing drug means that new patient groups can often be treated faster and better.
Investments in these ‘repurposed drugs’ are therefore utmost needed. Patent protection for new applications of existing drugs can act as a flywheel and contribute to a shorter time-to-market.
Patent attorney Barend Bouma explains, read the complete article in the FD paper about drug repurposing (p5).
Article BiotechNews
Drug repurposing p. 28-29
NLO colleagues Mari Korsten, Jaap Mannaerts and Barend Bouma wrote an interesting article for BiotechNews about “Unlocking the promise of drug repurposing”.
Clinical programs directed to drug repurposing bear the promise of providing new therapies for yet non-treatable diseases based on available therapeutics. First and foremost, by drug repurposing, new patients may get access to therapy perhaps for the first time, or current treatment may be improved.
Additional upsides can be that time to market, and therewith time to patient is shorter compared to drug development programs based on new drugs, and that costs are lower. Integrating the best of clinical research, timely patent protection and market control to support access for patients
The magazine Biotech News provides a platform for several interesting collaborations in biotechnology, where ‘Joining Forces’ takes a central role. Read the complete article by NLO experts here (page 28-29):
BiotechNews: Drug repurposing by NLO Pharma IP experts
Patent Attorneys
IP Specialists in Pharma
Patent Attorneys
IP Specialists in Pharma
